Investigation on Korean Tobacco Company KT&G by US Government

Business by 2FIRSTS.ai
Jan.18.2024
Investigation on Korean Tobacco Company KT&G by US Government
South Korea's largest tobacco company, KT&G, is under investigation by the US government for alleged violations of regulations.

According to a report from South Korean newspaper Dong-A Ilbo on January 18th, KT&G Corporation, the largest tobacco company in South Korea (also known as Han-Yan Ginseng), has confirmed that it is currently under investigation by the United States government. However, the company has stated that it has not received any notifications or penalties regarding any violation of regulations or laws.

 

Media reports have alleged that KT&G has been accused of violating regulations set by the US Department of Health, and of submitting inaccurate information during the approval and review processes for tobacco products. The media has also expressed concerns that KT&G may not be able to fully recover the 1.54 trillion Korean won (11.47 billion US dollars) long-term deposit it made to the US state government.

 

KT&G stated that, "Due to the intensified market competition following the enforcement of strengthened cigarette regulations on December 14, 2012, we need to reassess our business in the United States. We have issued a statement confirming that we have received a comprehensive document submission order from the US government." Furthermore, in the business report announcement on March 21, 2021, the company also reported to the board of directors on their response to the document submission order from the US Department of Justice (DOJ)."

 

In particular, in business reports, the holding company and its subsidiary, KT&G USA Corporation, have complied with the comprehensive document submission order from the US Department of Justice, providing necessary information regarding the regulatory compliance of locally sold cigarette products. However, the company currently expresses its inability to predict the final outcome of this investigation and its implications.

 

KT&G's position on concerns about the potential inability to fully recover long-term prepayments is to gradually refund them.

 

Prepayments from an illicit company's unlawful activities have resulted in harm to tobacco consumers, prompting the state government to allocate these funds towards the state's healthcare fund. However, in all other scenarios, according to regulations, reimbursements will be calculated from the date of self-payment and will be fully refunded after 25 years. Nevertheless, considering no particular issues regarding the company, KT&G believes there will be no problems with the reimbursement process. The refund period will commence in 2025.

 

KT&G stated that "the ongoing investigation is being conducted" and that "the US Department of Justice has requested confidentiality regarding the ongoing investigation, so we cannot confirm the specific details".

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

WIRED Investigation: Chinese-Made Vapes Turn to 6-Methyl-Nicotine and Other Analogs, Challenging U.S. Regulation
WIRED Investigation: Chinese-Made Vapes Turn to 6-Methyl-Nicotine and Other Analogs, Challenging U.S. Regulation
U.S. technology and investigative publication WIRED has examined how nicotine analogs are emerging as a new challenge for the country’s vape regulatory framework. The article argues that after the U.S. expanded federal oversight of nicotine products in 2022, some manufacturers began using nicotine-like compounds such as 6-methyl-nicotine that may fall outside existing definitions. Researchers cited by WIRED said some nicotine analogs could be more potent than traditional nicotine, although human health impacts remain unclear. U.S. policymakers are considering broader definitions of nicotine to bring these compounds under federal oversight.
Jul.27
Product | IQOS ILUMA i REMIX Limited Edition Launches in Japan, Bringing New Design Elements to Heated Tobacco Devices
Product | IQOS ILUMA i REMIX Limited Edition Launches in Japan, Bringing New Design Elements to Heated Tobacco Devices
Philip Morris Japan (PM Japan) has introduced the IQOS ILUMA i REMIX Limited Edition series, including the IQOS ILUMA i Prime REMIX, IQOS ILUMA i REMIX and IQOS ILUMA i ONE REMIX devices. The limited-edition models were officially announced in Japan on June 9, 2026, and began a phased market rollout from June 10. Featuring gradient color designs and visual customization elements, the collection highlights PMI’s continued use of limited editions to enhance brand experience within its heated tobacco portfolio.
Innovation
Jul.21 by 2Firsts Perspectives
Ireland Vape Bill Passes Dáil, Setting Limits on Flavours, Packaging and Retail Display
Ireland Vape Bill Passes Dáil, Setting Limits on Flavours, Packaging and Retail Display
Ireland’s Public Health (Tobacco Products and Nicotine Inhaling Products) (Amendment) Bill 2026 has passed final stage in the Dáil and will move to the Seanad, with measures to limit vape flavours to tobacco or unflavoured products and tighten rules on packaging colours, retail advertising, in-store displays and sales of nicotine pouches to minors.
News
Jun.26 by 2Firsts Perspectives
Illicit Vape and Nicotine Pouch Seizures Concentrated in UK Hotspots, New Data Shows
Illicit Vape and Nicotine Pouch Seizures Concentrated in UK Hotspots, New Data Shows
Freedom of Information (FOI) data from the UK shows that more than 3,000 seizures of illegal nicotine products were recorded in the 2024/25 financial year, with Hull, Liverpool and Bolton emerging as the most active enforcement hotspots — highlighting that the problem of illicit vapes, nicotine pouches and smokeless tobacco products persists across many parts of the country.
Jun.16
Germany Expands Take-Back Rules for Disposable Vapes From July 1
Germany Expands Take-Back Rules for Disposable Vapes From July 1
Germany has expanded take-back obligations for disposable vapes from July 1, 2026, requiring consumers to be able to return used devices at stores that sell such products, including kiosks, petrol stations and vape shops, as e-cigarette regulation extends from sales to waste management and lithium-battery safety.
Market
Jul.06 by 2Firsts Perspectives
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
CTT Pharmaceutical Holdings said it has signed a letter of intent with a U.S. company to conduct clinical trials and testing for several potential nicotine products using its patented oral thin-film technology.
Jun.18